News

London – In the current issue of Animal Pharm, Jamie Day reports on a new partnership which aims to introduce an innovative systemic drug delivery technology to the animal health market. The two partners, both from New Jersey in the US, claim that the platform obviates the need for needles while ensuring more of the active ingredient arrives at the target area.

NewMarket Pharmaceuticals of Princeton and Catalent Pharma Solutions, based in Somerset in the same state, have signed a global licensing agreement to develop and formulate a line of products for both food-producing and companion animals using Catalent’s Zydis fast dissolve oral tablet technology. The combination of Zydis and NewMarket’s Direct Systemic Introduction (DSI platform) will enable the partners to develop a portfolio of new animal health products that could provide “significant advantages over existing formulations currently used across a spectrum of indications.” [click to continue…]

NewMarket Pharmaceuticals LLC Initiates Development Of Products In ZYDIS® Fast Dissolving Tablets For Treatment Of Production And Companion Animals

Princeton, NJ – NewMarket Pharmaceuticals LLC has partnered with Catalent Pharma Solutions, a leading global drug delivery technology company, to develop and formulate a line of products for treating production and companion animals.  Using Catalent’s proprietary, market-leading Zydis® fast-dissolve technology and NewMarket’s own DSI™ platform (Direct Systemic Introduction, patent pending), NewMarket plans to develop a portfolio of new animal health products that are expected to provide significant advantages over existing formulations currently used across a spectrum of indications for companion animals, equine, and production animals.

NewMarket currently has five drugs in development that combine the Zydis® and DSI™ technologies, initially including NSAIDs, beta agonists, proton pump inhibitors, and behavior modifiers across a variety of species including horses, dogs, and cattle, with plans to expand the range in other classes. Mark Ridall, CEO of NewMarket Pharmaceuticals states that, “These easy-to-use formulations provide a clear advantage over traditionally ingested dosage forms and show the potential to revolutionize the way we treat animals by providing for a simple, efficient, accurate method of treatment without the use of needles.” [click to continue…]